<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067808</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0180</org_study_id>
    <nct_id>NCT00067808</nct_id>
  </id_info>
  <brief_title>Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if decitabine (given at 3 different
      doses) can help to control Myelodysplastic Syndrome (MDS). The safety of these 3 treatments
      will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment: Methylation is a change that occurs to Deoxyribonucleic acid (DNA) that has an
      effect on gene usage in human cells. Abnormal methylation is very common in leukemias.
      Decitabine is a new drug that blocks DNA methylation.

      Before treatment starts, a physical exam, blood tests (between 4-6 tablespoons), and a bone
      marrow study will be done. To collect a bone marrow sample, an area of the hip or chest bone
      is numbed with anesthetic and a small amount of bone marrow is withdrawn through a large
      needle. Women able to have children must have a negative blood or urine pregnancy test.

      When this study began, participants were randomly assigned (as in the toss of a coin) to one
      of 3 treatment groups. The assignment to one of the 3 schedules was adjusted according to how
      well patients respond to treatment. About 17 patients were assigned to each group for the
      first 50 patients.

      Participants in the first group received decitabine intravenously (IV--through a needle in
      their vein) over one hour, once a day, for 10 days. Treatment was given every 4 to 8 weeks
      depending on how well their blood counts recovered. Participants in the second group received
      decitabine as an IV infusion over one hour, once a day, for 5 days. Treatment was given every
      4 to 8 weeks. Participants who received decitabine by vein got the same total dose per
      course. Participants in the third group received decitabine by subcutaneous (SQ) injections
      (injections given under the skin) twice a day for 5 days. As in the first and second group,
      treatment was given every 4 to 8 weeks.

      After 65 patients were enrolled on this study, it was decided that the 5-day IV schedule was
      the best of the 3 schedules. The study will now continue with all new patients receiving the
      5 -day IV decitabine treatment. If you are now enrolling on the study, you will be placed in
      this treatment group, instead of being randomly assigned to a treatment group.

      Participants who are already on study and who are receiving the 5-day SQ schedule or the
      10-day IV schedule, will be given the option to change to the 5-day IV schedule at the start
      of their next course of study drug treatment, since this is considered the new &quot;standard&quot;
      schedule on this particular study.

      If you choose to take part in this study and begin receiving the study treatment described
      above, your response to treatment will be checked after completing 8 weeks of therapy. If the
      response to treatment is good, treatment with decitabine will continue. Decitabine treatment
      may be continued for up to 24 courses, or as long as it is judged best to control the
      leukemia.

      During this study, you will need to visit your doctor for a physical exam and vital signs.
      The frequency of doctor visits will vary depending on your physical condition, but will be
      required at least once a month.

      Blood tests (about 2 teaspoons) will be done about every week during the first 6-8 weeks of
      treatment, then every 1 to 2 weeks for the length of the study. The blood samples will be
      used for routine lab tests. Periodic bone marrow samples will also be taken to check cells
      related to the disease before, during, and after completion of this study.

      Patients will be taken off study if the disease gets worse or intolerable side effects occur.

      This is an investigational study. Decitabine is not yet Food and Drug Administration (FDA)
      approved.Up to 133 participants will be treated in this study. All will be enrolled at M. D.
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Responses</measure>
    <time_frame>Response to treatment after 8 weeks of therapy</time_frame>
    <description>Objective responses by International Working Group criteria: 'Complete Response' (CR) defined as Normalization of the peripheral blood and bone marrow with &lt;5% bone marrow blasts, a peripheral blood granulocyte count &gt; (1.0 x 109/ L, and a platelet count &gt; 100 x 109/L); 'Other Response' including Partial Remission (PR) defined as above, except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment combined with participants who meet all criteria for CR except for platelet recovery to &gt;100 x 109/L; and 'No Response'.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine 10 mg/m^2 IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/m^2 intravenous (IV) over 1 hour daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine 20 mg/m2 IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/m2 IV over 1 hour daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine 20 mg/m2 SQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/m2 subcutaneous (SQ) daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>10 mg/m^2 by vein over 1 hour daily for 10 days</description>
    <arm_group_label>Decitabine 10 mg/m^2 IV</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>20 mg/m2 by vein (IV) over 1 hour daily x 5 days</description>
    <arm_group_label>Decitabine 20 mg/m2 IV</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>20 mg/m2 subcutaneous (SQ) daily x 5 days</description>
    <arm_group_label>Decitabine 20 mg/m2 SQ</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or
             chronic myelomonocytic leukemia

          2. Performance status 0-2 (Eastern Cooperative Oncology Group (ECOG) scale); adequate
             hepatic (bilirubin &lt; 2 mg/dl) and renal functions (creatinine &lt;2mg/dl); New York Heart
             Association (NYHA) cardiac status III-IV excluded.

          3. Signed informed consent

          4. No prior intensive combination chemotherapy or high-dose ara-C (&gt;/= 1g/m2 per dose).
             Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.

          5. Patients must have been off chemotherapy for 2 weeks prior to entering this study and
             recovered from the toxic effects of that therapy, unless there is evidence of rapidly
             progressive disease. Use of Hydroxyurea for patients with rapidly proliferative
             disease is allowed for the first two weeks on therapy.

        Exclusion Criteria:

          1. Nursing and pregnant females are excluded. Patients of childbearing potential should
             practice effective methods of contraception. Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately.

          2. Patients with active and uncontrolled infections

          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or
             psychiatric illness/social situations that would limit compliance with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M Kantarjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M.D. Anderson Cancer Center's website</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2003</study_first_submitted>
  <study_first_submitted_qc>August 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2003</study_first_posted>
  <results_first_submitted>September 25, 2009</results_first_submitted>
  <results_first_submitted_qc>April 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2011</results_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>Decitabine</keyword>
  <keyword>Dacogen</keyword>
  <keyword>Methylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 6/4/03 - 5/18/09; all patients were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Enrollment of 128 patients: 1 patient withdrew consent prior to treatment; 3 did not meet eligibility requirement for a total of 124 evaluable patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Decitabine 10 mg/m2 IV</title>
          <description>10 mg/m2 by vein (IV) over 1 hour daily for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Decitabine 20 mg/m2 IV</title>
          <description>20 mg/m2 IV over 1 hour daily for 5 days</description>
        </group>
        <group group_id="P3">
          <title>Decitabine 20 mg/m2 SQ</title>
          <description>20 mg/m2 subcutaneous (SQ) daily for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Decitabine 10 mg/m2 IV</title>
          <description>10 mg/m2 by vein (IV) over 1 hour daily for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Decitabine 20 mg/m2 IV</title>
          <description>20 mg/m2 IV over 1 hour daily for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Decitabine 20 mg/m2 SQ</title>
          <description>20 mg/m2 subcutaneous (SQ) daily for 5 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="B2" value="65" lower_limit="37" upper_limit="83"/>
                    <measurement group_id="B3" value="64" lower_limit="51" upper_limit="79"/>
                    <measurement group_id="B4" value="65" lower_limit="37" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant Responses</title>
        <description>Objective responses by International Working Group criteria: 'Complete Response' (CR) defined as Normalization of the peripheral blood and bone marrow with &lt;5% bone marrow blasts, a peripheral blood granulocyte count &gt; (1.0 x 109/ L, and a platelet count &gt; 100 x 109/L); 'Other Response' including Partial Remission (PR) defined as above, except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment combined with participants who meet all criteria for CR except for platelet recovery to &gt;100 x 109/L; and 'No Response'.</description>
        <time_frame>Response to treatment after 8 weeks of therapy</time_frame>
        <population>As treated: 124 patients completed treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Decitabine 10 mg/m2 IV</title>
            <description>10 mg/m2 by vein (IV) over 1 hour daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Decitabine 20 mg/m2 IV</title>
            <description>20 mg/m2 IV over 1 hour daily for 5 days</description>
          </group>
          <group group_id="O3">
            <title>Decitabine 20 mg/m2 SQ</title>
            <description>20 mg/m2 subcutaneous (SQ) daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Responses</title>
          <description>Objective responses by International Working Group criteria: 'Complete Response' (CR) defined as Normalization of the peripheral blood and bone marrow with &lt;5% bone marrow blasts, a peripheral blood granulocyte count &gt; (1.0 x 109/ L, and a platelet count &gt; 100 x 109/L); 'Other Response' including Partial Remission (PR) defined as above, except for the presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment combined with participants who meet all criteria for CR except for platelet recovery to &gt;100 x 109/L; and 'No Response'.</description>
          <population>As treated: 124 patients completed treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Decitabine 10 mg/m2 IV</title>
          <description>10 mg/m2 by vein (IV) over 1 hour daily for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Decitabine 20 mg/m2 IV</title>
          <description>20 mg/m2 IV over 1 hour daily for 5 days</description>
        </group>
        <group group_id="E3">
          <title>Decitabine 20 mg/m2 SQ</title>
          <description>20 mg/m2 subcutaneous (SQ) daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cardipulmonary arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Elevated cardiac triponin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Prolonged myelosuppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hagop Kantarjian, MD / Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713-792-7026</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

